{"id":343720,"date":"2025-08-14T11:25:20","date_gmt":"2025-08-14T11:25:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/343720\/"},"modified":"2025-08-14T11:25:20","modified_gmt":"2025-08-14T11:25:20","slug":"interview-why-the-eu-critical-medicines-act-brings-challenges-but-also-opportunities","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/343720\/","title":{"rendered":"Interview: why the EU Critical Medicines Act brings challenges, but also opportunities"},"content":{"rendered":"


\n
\n
\n
\n
\n <\/p>\n


\n Updated as of: 14 August 2025<\/strong> \n <\/p>\n


\n
\n
\n
\n <\/p>\n


\n
\n <\/a><\/p>\n


\n <\/p>\n


\n \"Lexology
\n <\/a>
\n
\n
\n
\n
\n
\n
\n
\n The EU\u2019s new Critical Medicines Act may bring extra obligations for pharma companies, but new opportunities will make the investment worth it, according to global pharma and biotech consultant Rashmi Chaturvedi Upadhyay.
\n
\n
\n
\n
\n
\n Filed under
\n
\n Topics
\n
\n Industries
\n
\n
\n
\n
\n <\/p>\n","protected":false},"excerpt":{"rendered":" Updated as of: 14 August 2025 …\n","protected":false},"author":2,"featured_media":302279,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5174],"tags":[122166,982,2000,299,5187,1699,36257,2725,111522,111518,111519,111517,7900,111525,111526,111524,111521,111527,111523,111520,5489,1828],"class_list":{"0":"post-343720","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-company-commercial","9":"tag-deals","10":"tag-eu","11":"tag-europe","12":"tag-european","13":"tag-european-union","14":"tag-force-majeure","15":"tag-law","16":"tag-law-developments","17":"tag-law-firms","18":"tag-law-updates","19":"tag-lawyers","20":"tag-legal","21":"tag-legal-advisers","22":"tag-legal-advisors","23":"tag-legal-current-awareness","24":"tag-legal-developments","25":"tag-legal-directory","26":"tag-legal-newsletters","27":"tag-legal-updates","28":"tag-pharmaceuticals","29":"tag-supply-chain"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115026875211058066","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/343720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=343720"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/343720\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/302279"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=343720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=343720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=343720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}